Propranolol effective and safe treatment option for IH even in infants less than 5 weeks
Propranolol appears to be an effective and safe treatment option for IH in infants <5 weeks corrected age according to a recent study published in the Pediatric Dermatology
Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established. The objective of this study was to assess the safety and efficacy of propranolol for treatment of IH in infants <5 weeks corrected age, or 45 weeks corrected gestational age (CGA).
They performed a single institution, retrospective review of patients treated with propranolol prior to the age of 6 months between 2017 and 2021. Patient characteristics, location of hemangioma(s), weight at the initiation of treatment, dosing information, side effects, response, and duration of treatment were documented.
Of 200 patients with IH treated with propranolol, 24 started treatment prior to 45 weeks CGA. Mean CGA at the initiation of treatment was 42 weeks. Sixty-seven per cent were female and 75% were white, non-Hispanic. The mean duration of treatment was 255 days. Twenty-two patients (92%) had clear benefit from treatment at a dose of 1-3 mg/kg/day. The most common side effects were sleep disturbance (21%), irritability (17%), and cool hands/feet (13%). There were no serious adverse events.
Thus, in this cohort of 24 patients with corrected age <5 weeks (CGA <45 weeks), propranolol was safe and effective for the treatment of infantile hemangiomas. Larger, prospective studies are indicated to investigate propranolol in this age group.
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age by Jorie E Gatts et al. published in the Pediatric Dermatology
Propranolol, effective and safe treatment option for IH, safe treatment option for IH in infants <5 weeks, management of IH, infantile hemangioma in infants, infantile hemangioma in infants cure, infantile hemangioma in infants and propranolol, Pediatric Dermatology, Jorie E Gatts, Marie C Rush , Jennifer F Check, Diane M Samelak, Thomas W McLean